These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25699475)

  • 1. Evolution of oncolytic viruses.
    Sanjuán R; Grdzelishvili VZ
    Curr Opin Virol; 2015 Aug; 13():1-5. PubMed ID: 25699475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directing systemic oncolytic viral delivery to tumors via carrier cells.
    Nakashima H; Kaur B; Chiocca EA
    Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic viruses: perspectives on clinical development.
    Burke J; Nieva J; Borad MJ; Breitbach CJ
    Curr Opin Virol; 2015 Aug; 13():55-60. PubMed ID: 25989094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modification of oncolytic viruses to enhance antitumor immunity.
    Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
    Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile.
    Guo L; Hu C; Liu Y; Chen X; Song D; Shen R; Liu Z; Jia X; Zhang Q; Gao Y; Deng Z; Zuo T; Hu J; Zhu W; Cai J; Yan G; Liang J; Lin Y
    Nat Commun; 2023 Jun; 14(1):3410. PubMed ID: 37296165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.
    Wennier ST; Liu J; McFadden G
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1817-33. PubMed ID: 21740354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
    Cuddington BP; Mossman KL
    J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer.
    Bell JC; McFadden G
    Curr Opin Virol; 2015 Aug; 13():viii-ix. PubMed ID: 26260227
    [No Abstract]   [Full Text] [Related]  

  • 17. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
    Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
    Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
    Kuhn I; Harden P; Bauzon M; Chartier C; Nye J; Thorne S; Reid T; Ni S; Lieber A; Fisher K; Seymour L; Rubanyi GM; Harkins RN; Hermiston TW
    PLoS One; 2008 Jun; 3(6):e2409. PubMed ID: 18560559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.